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Brief description of the novelty and impact of the work 





The aim of this work was to answer the question whether the  broad range of parameters which describe oxidative stress and oxidatively damaged DNA and repair are appropriate prognosis factors of colon cancer (CRC) patients survival? The following parameters were analyzed for 89 CRC patients: concentration of uric acid and vitamins A, E, C in plasma; levels of 8-oxodGuo (8-oxo-7,8-dihydro-2'-deoxyguanosine) in DNA of leukocyte and colon tissues; urinary excretion rates of 8-oxodGuo and 8-oxoGua (8-oxo-7,8-dihydroguanine); the activity and mRNA or protein level of repair enzymes OGG1, APE1, ANPG, TDG and PARP1.
All DNA modifications and plasma antioxidants were analyzed using high performance liquid chromatography (HPLC) or HPLC/gas chromatography-mass spectrometry techniques. Expression of repair proteins was analyzed by QPCR, Western or immunohistochemistry methods.




Oxidatively damaged DNA has often been blamed as a possible basis for the physiological changes associated with degenerative diseases such as cancer. 8-oxo-7,8-dihydroguanine (8-oxoGua), one of the oxidatively modified DNA bases, is a typical biomarker of oxidative stress and may play a role in carcinogenesis. The presence of 8-oxoGua residues in DNA leads to GC to TA transversion unless repaired prior to DNA replication. Many observations indicate a direct correlation between 8-oxoGua formation and mutagenesis/carcinogenesis in vivo [for review see 1-3].
Several DNA repair pathways have evolved that protect organisms subject to oxidative stress from the deleterious effects of DNA damage. Excision of 8-oxoGua from DNA is accomplished mainly by base excision repair (BER) and the major enzyme catalyzing the removal of 8-oxoGua is the OGG1 DNA glycosylase 4,5.
Another protein which plays a regulatory role in BER is PARP-1 (poly [ADP-ribose] polymerase 1), which is a molecular sensor of DNA breaks 6. Moreover, PARP-1 is activated in response to DNA damage including oxidatively modified nucleotides 7,8. PARP-1 deficient cells are sensitive to DNA damage, and enzyme depletion results in increased conversion of single-strand breaks into double strand breaks 9. That is why inhibitors of this key repair enzyme have been successfully introduced into the clinic to treat breast and other cancers 10. There are experimental reports about the decrease in DNA repair efficiency in cancer patients suffering from some, but not all types of cancer 11-13.
	Excretion of 8-oxodGuo/8-oxoGua with urine represents the average rate of oxidative stress/DNA damage in the whole body. Therefore, an increased level of urinary 8-oxodGuo/8-oxoGua may represent changes in the rate of oxidative stress/oxidatively damaged DNA. If possible the excretion rate should be combined with measurement of 8-oxodGuo in cellular DNA to study the question of rates of repair versus rates of damage (assuming rates of repair are the same in all cells/cell types of the body).
	In a recently published paper 14 we demonstrated the existence of oxidative stress in  colorectal carcinoma patients (CRC) and in patients with a precancerous condition - benign adenoma individuals (AD). This was accompanied by increased transcription of DNA repair genes (APE1, OGG1, MTH1), and increased 8-oxoGua excision rate in blood leukocyte of CRC patients. However, despite higher expression of the aforementioned genes (at mRNA level) involved in DNA repair process, the oxidatively damaged DNA biomarker, namely 8-oxodGuo level in DNA of blood leukocyte, was elevated both in CRC patients and AD individuals in relation to healthy volunteers. Seemingly, the higher expression of these genes was insufficient to counteract the increased DNA damage.
	Many patients, including those with early stage of colon cancer, experience recurrence after surgical resection and die as a result of the disease, despite potentially curative treatment. In view of the above mentioned consideration, we searched for new biomarkers, which reflect oxidative stress/DNA damage and may be helpful to more accurately correlate cancer staging with disease outcome which, in turn, may be helpful to identify high risk colon cancer patients in order to apply proper curative treatment.




The CRC patient group (n = 89) comprised 45 males and 44 females (median age 62 years, range 27– 90). All participants were Caucasians and there were no relatives among them. All individuals participating in the study were recruited through the hospital (Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland) and were examined by colonoscopy.
The CRC patient population were divided into two groups: 
-	1st group with low levels of the analysed parameters; between minimum value and median (values < median);
-	2nd group with high values; ranging from median to maximum value of the analysed parameters (values ≥ median).
The resulting groups comprised an approximately equal number of patients. 
All of the patients had histologically proven adenocarcinoma and the tumours were staged according to TNM classification, using numerals I, II, III, and IV to describe the progression of cancer. Cancer  cells consist of approximately 70% of removed tumour sample, while in marginal tissue there were no single tumour cell. The marginal tissue were in the distance of 5-50 cm apart from the tumour.
All the subjects, when recruited to the study, filled in the questionnaire concerning demographic data, smoking, diet and medical history. Interviewees were asked to estimate the average frequency of consumption of various dietary items in the year proceeding the interview. The majority of them reportedly consumed 3 servings of fruit and vegetables and about 250 g of meat and fat per day. To make the group even more homogenous, the subjects who reported the extreme consumption, as well as those who reported supplementation within the last month were excluded from the study.
Venous blood samples were withdrawn from patients in the morning before breakfast. Overnight spot urine samples were collected. Although the 24 h excretion is the gold standard, correction for creatinine is the next preferred option. Therefore,  in the present study urine were collected as spot samples and the concentrations of  8-oxodGuo and 8-oxoGua was adjusted by the creatinine concentration. Spot morning urine samples can be used to determine excretion rate assuming that creatinine excretion is unchanged like in our work (i.e. in a clinical controlled trial). Importantly, it was found that there is the statistically significant correlation of the urinary excretion between morning spot urine samples corrected for creatinine excretion and 24 h urine samples 16. Moreover, we didn’t find significant difference between men and women (respective values were 12.5 and 10.5 nmol/mmol creatinine).

Measurement of oxidative stress biomarkers in tissues/ urine and expression of repair proteins
All DNA modifications and plasma antioxidants were analyzed using high performance liquid chromatography/electrochemical detection (HPLC/EC/UV/FD, HPLC/UV/FD) or HPLC/gas chromatography-mass spectrometry (GC-MS) techniques. Expression of repair proteins was analyzed by QPCR, or Western methods. All methods have been described in detail elsewhere 14,17.

Immunohistochemistry
Blocks with  pieces of tissue embedded in paraffin were cut into 4.0 μm thick sections on microtome Accu-Cut SRM 200 (Sakura Finetek Europe B.V., Netherlands), placed on SuperFrost glass slides (Thermo Scientific, USA) and dried at 58°C for 1h. For immunohistochemical analysis the paraffin tissue sections were dewaxed with xylene and gradually hydrated in decreasing series of alcohol (100, 96, 90, 70%) and finally brought to water. After antigens retrieval (Dako Target Retrieval solution high pH; catalogue number K8000; Dako) at 95°C for 20 minutes and blocking endogenous peroxidases activity in 3% H2O2 at room temperature for 10 minutes, the slides were incubated in PBS-Tween buffer containing 5% BSA for blocking unspecific staining also at room temperature for 10 minutes. Subsequently the sections were incubated with primary rabbit monoclonal antibody against PARP (catalogue number ab32138; abcam) or rabbit polyclonal antibody directed to hOGG1 (catalogue number NB100-106SS; Novus Biologicals, USA). The incubation with primary antibodies (diluted respectively 1:50 and 1:500 in PBS containing 1.0% BSA) was carried out  overnight at 4°C in a moist chamber. After being washed twice with PBS-Tween, the slides were incubated using the anti-rabbit EnVision peroxidase detection system (catalogue number K4011 Dako) for 1h at room temperature. For chromogenic detection a DAB detection kit was used (catalogue number SM 803, SM827; Dako). After rinsing in distilled water, the sections were counterstained with haematoxylin, dehydrated in increasing grades of alcohol (70, 90, 96, 100% v/v) and finally mounted with Shandon Consul Mount (Thermo Scientific). Negative controls were prepared using the same procedure except that the primary antibody was replaced with 1% BSA in PBS. 

Morphometric analysis
Specimens were examined with a light microscope (Eclipse E800, Nikon) equipped with cooled CD camera (Nikon Digital Sight DS-5Mc, Germany) driven by NIS Elements F 3.0 software (Nikon, Germany). The expression levels of antigens were evaluated in terms of the labelling intensity of the cell’s compartments after immunohistochemical detection of analyzed antigens. For this purpose we used a method described before by Remmele and Stegner 18. The scoring system (IRS) took into account the intensity of the colour reaction (SI) and the percentage of positive cells (PP) within the 5 microscope fields at the magnification of 200x. The final score represented a product of scores (SI x PP) and ranged from 0 to 12 points (low reaction: 1 to 2 points, average reaction: 3 to 4 points, intense reaction: 6 to 12 points).
Statistical analyses
The CRC patient population was divided into two groups, see above “Study Group” section. To summarize the data the following descriptive statistics: median, minimum and maximum values in the total study population were calculated for each quantitative variable.
	For the statistical analysis the STATISTICA (version 10.0) computer software (StatSoft, Inc) was used. Differences between categorized groups were assessed with using the log-rank and F Cox tests. Overall Survival Probability (OSP) was calculated at 60 months. Statistical significance was considered at p<0.05.

RESULTS 
Patients (n = 89) were followed 100 months after surgery or until death. By the end of the study period 38 patients had died from CRC (n = 4), metastasis (n = 24) or other reasons (n = 10). Survival analysis was used to determine the prognostic value of each of the analysed parameters: concentration of uric acid and vitamins A, E, C in plasma; levels of 8-oxodGuo in DNA of leukocyte and colon tissues; excretion rates of urinary 8-oxodGuo and 8-oxoGua individually or in combination. The levels of mRNA or protein of repair enzymes, OGG1, APE1, ANPG, TDG and PARP-1 were also determined. Only some of all analysed biomarkers were significant predictors of CRC patient survival. 
	Among plasma antioxidants only uric acid level coincided with longer survival. Patients with low uric acid plasma level (values lower than 277.8 µM) lived less long than those with high uric acid level (OSP60=40% vs 66% respectively; p=0.006; Fig. 1A). Another marker of global oxidative stress, 8-oxodGuo in urine was lower (values below 1.78 nmol/mmol creatinine) in longer survivors than in patients with worse prognosis (OSP60=70% vs 56% respectively; p<0.05; Fig. 1B). 8-oxodGuo in urine most probably derives from oxidation of deoxynucleotides pool, and thus reflects oxidative processes in the whole organism. Urinary 8-oxoGua is probably a product of excision by DNA glycosylases, of which OGG1 is thought to be the major one. Low urinary level of 8-oxoGua (values lower than 10.12 nmol/mmol creatinine) was associated with longer survival of CRC patients (OSP60=77% vs 52%; p=0.01; Fig. 1C). Similarly, lower mRNA level of OGG1 glycosylase in histologically unchanged colon tissue was observed in patients who survived longer (OSP60=74% vs 47%; respectively; p<0.05; Fig. 2A). This might suggest that lower 8-oxoGua excision rate could be correlated with longer survival; however, no such relationship was found (not shown). This might be due to the fact that OGG1 activity is affected by several factors, and posttranslational modifications change both cellular localization of protein and its activity 14,19. Interestingly, high PARP-1 protein expression in normal colon or in cancer tissue did not affect patients' mean survival time (OSP60=54% vs 66%; p=0.13; Fig 2B).
	When further comparing DNA oxidation with survival probability of CRC patients we observed that low 8-oxodGuo in cancerous colon tissue (values below 4.32 8-oxodGuo/106 dG) coincided with longer survival (OSP60=69% vs 47%, respectively; p<0.05; Fig. 3A). Association of low 8-oxodGuo level in leukocyte (values below 6.31 8-oxodGuo/106 dG) with higher survival probability was close to the border of statistical significance (OSP60=73% vs 57%; p=0.055; Fig. 3B). 
	For combinatorial analysis only parameters which do not correlate with each other were taken into consideration. Combinatorial analysis of urinary levels of 8-oxoGua with leukocyte 8-oxodGuo resulted in much better prediction of survival time than when analysing any of these markers separately. Simultaneous low levels of urinary 8-oxoGua (values below 10.12 nmol/mmol creatinine) and leukocyte 8-oxodGuo (values below 6.31 8-oxodGuo/106 dG) were associated with longer survival of CRC patients than of those with higher levels of these markers (OSP60=87% vs 22%, respectively; p=0.00001; Fig 4A). 
	When analyzing the levels of plasma uric acid in combination with leukocyte 8-oxodGuo or urinary 8-oxoGua it was found that patients with low 8-oxodGuo in leukocyte and high plasma uric acid (above 277.8 µM) had much better survival prognosis than patients with high leukocyte 8-oxodGuo and low plasma uric acid (OSP60=89% vs 55%; p<0.007; Fig. 4B). Similar differences in overall survival were observed in individuals with low urinary 8-oxoGua and high uric acid (OSP60=88% vs 37%; p=0.0009; Fig. 4C). 
Combinatorial analysis of three markers (uric acid, urinary 8-oxoGua and 8-oxodGuo in DNA of leukocyte) did not improve the prediction power over aforementioned combination of two markers (Fig.4D). 
	These results suggest that combination of urinary 8-oxoGua with leukocyte 8-oxodGuo level and with plasma uric acid concentration may be a valuable predicting tool for colon cancer therapy outcome. As expected survival prognosis reversely correlated with the histologically determined stage of the tumour (Fig. 5). It is noteworthy that there is no significant correlation between the staging and all the parameters used for combinatorial analysis with respective p values for: urinary 8-oxoGua - 0.31; leukocyte 8-oxodGuo level -0.48 and plasma uric acid - 0.53. 

Discussion
The gold standard to predict prognosis in colorectal cancer (as well as other cancer types) is the pathological staging of the tumour after surgery. However, often patients with the same tumour stages demonstrated quite different clinical outcome. This in turn suggests that the conventional procedure is unable to precisely predict cancer patient prognosis 20,21. Several studies demonstrated that oxidative stress is induced at an early stage of colon cancer development and is intensified during cancer progression 2,14. Thus, it is possible that determination of oxidative stress/DNA damage and repair biomarkers together with the staging may be helpful to predict clinical outcome of the disease more precisely, which, in turn, may help to identify high-risk groups of patients and may allow to improve cancer treatment options.
A comparative analysis of survival prognosis with respect to individual markers revealed that a significant increase in total survival was found in the group of patients with (i) low expression of OGG1 mRNA in marginal tissues; (ii) low level of urinary excretion rate of 8-oxoGua - values lower than 10.12 nmol/mmol creatinine; (iii) low level of urinary excretion rates of 8-oxodGuo - values below 1.78 nmol/mmol creatinine; (iv) high level of uric acid in blood - values higher than 277.8 µM; (v) low level of 8-oxodGuo in DNA of cancerous tissue - values below 4.32 8-oxodGuo/106 dG; and (vi) low level of 8-oxodGuo in leukocyte DNA - values below 6.31 8-oxodGuo/106 dG (Figs. 1-3; although two aforementioned markers (8-oxodGuo in DNA of cancerous tissue and in leukocyte) were on the borderline of statistical significance). Low urinary excretion rate of 8-oxoGua together with low level of 8-oxodGuo in leukocyte DNA or high level of uric acid and low level of 8-oxodGuo in leukocyte DNA together with high concentration of uric acid were the best combination of  the markers predicting long-term survival (Fig. 4).
Since the aforementioned parameters represent oxidative stress/DNA damage on the level of the whole organism an important question is why they are the most meaningful in predicting longer survival of cancer patients. It should be remembered that the level of the modified base in urine may be an indicator of oxidative insult to DNA and general marker of oxidative stress 22.
In our previous work we demonstrated that urinary 8-oxoGua and the level of 8-oxodGuo in leukocyte DNA could be regarded as markers to predict the clinical success of radiotherapy of head and neck patients. More importantly in the good-prognosis group  there was lower pre-radiation 8-oxoGua level in urine than in the whole population 23. Therefore, it is possible that lower initial oxidative stress/DNA damage, represented by urinary 8-oxoGua, is one of the parameters which may predict longer survival time in the overall cancer disease. 
Since oxidative stress is closely linked with chronic inflammation 24, the high level of urinary 8-oxoGua may likely mirror the severity of the disease. Indeed, several studies have demonstrated that factors which reflect inflammation may be associated with the pathological staging of the tumour or to be tumour stage independent prognostic factors 25. In addition the prooxidative environment may confer a growth advantage to tumour cells, and more generally, it may influence carcinogenic potential by  stimulating specific signaling cascades that regulate cell growth and apoptosis 26. It is noteworthy that although the role of oxidative stress in carcinogenesis appears well established the quantitative relationship between the oxidatively damaged DNA and cancer is still lacking 1,24.
Leukocyte are often used as surrogate cells, which are supposed to inform about oxidative stress in other tissues, which is measured as a certain level of 8-oxodGuo in leukocyte DNA 27,28. Since the background level of 8-oxoGua in cellular DNA represents a dynamic equilibrium between rate of oxidative DNA damage formation and rate of repair of the damage in that specific tissue/cells, it is likely that low level in the surrogate tissue in addition to low oxidative stress reflects efficient removal of the damage.
There are great individual differences with respect to coping with oxidative stress/DNA damage reflected in substantial differences in levels of antioxidants, urinary and cellular 8-oxodGuo level 14. Therefore, the possibility exists that this variability may partially account for the differences in cancer patient prognosis. This variability may reflect individual differences in the metabolism of different oxidants and DNA repair capacity and, at least in part, genetic background 29,30. 
Surprisingly we found that uric acid level is the only antioxidant with significant power to predict survival time. Moreover, high level of uric acid in combination with low level of 8-oxodGuo in leukocyte DNA or low urinary excretion rate of 8-oxoGua is the best predictor of longer survival time (Fig. 4B). This finding may be explained in the context of studies which demonstrate that uric acid in physiological concentration is a main antioxidant and not only efficiently scavenges free radicals but  has also been shown to stabilize ascorbic acid in human serum 31 and reduces consumption of -tocopherol and -carotene 32. In addition uric acid level may mirror cancer cell death 33. Indeed, it has been shown that tumours in which there is increased cell death show elevated levels of uric acid and dying tumour cells release uric acid 33,34. Moreover, uric acid is a danger signal which can potentiate the immune system to fight cancer 33. On the other hand in very high concentration (about 420 μM) uric acid may trigger inflammation [reviewed in 35].
There is inconsistency in the assessment of the usefulness of oxidative DNA damage as a prognostic factor in different types of cancer. In colorectal, small cell lung cancer and renal cell carcinoma high 8-oxodGuo level estimated by immunostaining was associated with a poor prognosis 36-39. Surprisingly breast cancer patients lacking both 8-oxodGuo and OGG1 also had poor survival prognosis 40. The inconsistencies may, at least partially, depend on the antibody used for immunostaing since the antibody used for 8-oxodGuo detection may be cross-reactive towards other compounds and the method does not allow for damage quantification 22,41,42.
In our work 8-oxodGuo in DNA was analyzed with reliable HPLC/EC technique. However, 8-oxodGuo in cancerous and marginal colon tissue was not the best predictor and its prediction power was on the borderline of statistical significance (data not shown). 
Interestingly, a better survival prognosis was correlated with low mRNA level of the main 8-oxoGuo glycosylase, OGG1 in marginal colon tissue (Fig. 2). OGG1 is engaged in activating transcription of Myc and estrogen receptor regulated genes 43, and it was found that OGG1 may be responsible for transcriptional activation of inducible nitric oxide synthase 44. OGG1 deficiency may, thus, protect against inflammation and mutations. 
In conclusion, since the major factors which are involved in colon cancer development; inflammation, fat metabolism/consumption of meat, cigarette smoking and  alcohol, are also responsible for ROS generation, herein we decided to check whether the parameters which describe oxidative stress/DNA damage may be used as a marker to predict the survival of CRC patients. The results of our work suggest that although some of these markers have significant values on their own, used in combination (urinary 8-oxoGua together with uric acid or 8-oxodGuo in leukocyte DNA ) have  much greater predictive value. Likely, these parameters filtered out patients: (i) with lower oxidative stress/efficient removal of oxidatively damaged DNA; and (ii) with the ability to remove cancerous cells more efficiently. Their prediction value seems to be comparable to conventional staging procedure (compare Figs. 4 and 5). Since there is no correlation between the staging and the analysed markers (see the Results section) it seems reasonable to suggest that their use together with clinicopathological staging procedure may help with better selection of therapeutic options. It is also noteworthy that the measurement of oxidatively generated DNA damage products or uric acid offers a means by which overall survival may be assessed non-, or minimally, invasively .
Recently we have shown that oxidatively damaged DNA is inversely correlated with the endogenous level of antioxidant vitamins and uric acid 45,46. Since the vitamin level may depend both on genetic make up and diet/suplementation our results suggests that increased intake of vitamins/antioxidants especially in high risk group (with high levels of 8-oxodGuo in leukocyte DNA/urinary 8-oxoGua and low  uric acid concentration) may be an important factor to slow down colon cancer development. However, there is only limited evidence concerning a protective effect of diet on the risk of CRC (for review see 47).
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Figure legend    
Fig. 1. Relation between the global oxidative stress biomarkers, plasma uric acid (A), urinary 8-oxodGuo (B) and urinary 8-oxoGua levels (C) and survival of CRC patients following surgery.
Fig. 2. OGG1 glycosylase mRNA level (A) and PARP1 protein level (B) in normal colon tissue and the time of survival of CRC patients following therapeutic surgery.
Fig. 3. Relation between the level of 8-oxodGuo in cancerous colon tissue (A), and in leukocyte (B) and survival of CRC patients following surgery.
Fig. 4. Combinatorial comparison of leukocyte 8-oxodGuo level and urinary 8-oxoGua (A), leukocyte 8-oxodGuo level and plasma uric acid (B), urinary 8-oxoGua and plasma uric acid levels (C) as well as leukocyte 8-oxodGuo, urinary 8-oxoGua and uric acid (D) with survival probability of CRC patients.
Fig. 5. Survival prognosis in relation to the stage of tumour development.
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